Adastra, Per A.Durand, Neva C.Mitra, NamitaPulido, Saul GodinezMahajan, RaginiBlackburn, AlyssaColaric, Zane L.Theisen, Joshua W. M.Weisz, DavidDudchenko, OlgaGnirke, AndreasRao, Suhas S. P.Kaur, ParwinderAiden, Erez LiebermanAiden, Aviva Presser2024-05-032024-05-032023Adastra, P. A., Durand, N. C., Mitra, N., Pulido, S. G., Mahajan, R., Blackburn, A., Colaric, Z. L., Theisen, J. W. M., Weisz, D., Dudchenko, O., Gnirke, A., Rao, S. S. P., Kaur, P., Aiden, E. L., & Aiden, A. P. (2023). A rapid, low-cost, and highly sensitive SARS-CoV-2 diagnostic based on whole-genome sequencing. PLOS ONE, 18(11), e0294283. https://doi.org/10.1371/journal.pone.0294283https://hdl.handle.net/1911/115560Early detection of SARS-CoV-2 infection is key to managing the current global pandemic, as evidence shows the virus is most contagious on or before symptom onset. Here, we introduce a low-cost, high-throughput method for diagnosing and studying SARS-CoV-2 infection. Dubbed Pathogen-Oriented Low-Cost Assembly & Re-Sequencing (POLAR), this method amplifies the entirety of the SARS-CoV-2 genome. This contrasts with typical RT-PCR-based diagnostic tests, which amplify only a few loci. To achieve this goal, we combine a SARS-CoV-2 enrichment method developed by the ARTIC Network (https://artic.network/) with short-read DNA sequencing and de novo genome assembly. Using this method, we can reliably (>95% accuracy) detect SARS-CoV-2 at a concentration of 84 genome equivalents per milliliter (GE/mL). The vast majority of diagnostic methods meeting our analytical criteria that are currently authorized for use by the United States Food and Drug Administration with the Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization require higher concentrations of the virus to achieve this degree of sensitivity and specificity. In addition, we can reliably assemble the SARS-CoV-2 genome in the sample, often with no gaps and perfect accuracy given sufficient viral load. The genotypic data in these genome assemblies enable the more effective analysis of disease spread than is possible with an ordinary binary diagnostic. These data can also help identify vaccine and drug targets. Finally, we show that the diagnoses obtained using POLAR of positive and negative clinical nasal mid-turbinate swab samples 100% match those obtained in a clinical diagnostic lab using the Center for Disease Control’s 2019-Novel Coronavirus test. Using POLAR, a single person can manually process 192 samples over an 8-hour experiment at the cost of ~$36 per patient (as of December 7th, 2022), enabling a 24-hour turnaround with sequencing and data analysis time. We anticipate that further testing and refinement will allow greater sensitivity using this approach.engExcept where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license. Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.Journal articlejournal-pone-0294283https://doi.org/10.1371/journal.pone.0294283